Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study
Authors' conclusion
Gout flare occurred in 18% of patients with comorbid gout hospitalized for COVID-19 and added up to 3 days to hospital length of stay.
Study context
- Population
- Adults with comorbid gout hospitalised for PCR-confirmed COVID-19, March 2020–December 2021, 3 hospitals in Thailandof 8697 hospitalised for COVID-19
- Participants
- 146 adults
- Exposure
- Gout flare vs no gout flare
- Gout flaren = 26
- Outcome
- Prevalence of gout flare
Methodological detailsmulticentre, LASSO selection and multivariate logistic regression, multivariate linear regression
- Multicentre
- LASSO selection and multivariate logistic regression
- Multivariate linear regression
Main finding
As reported in the abstract
Gout flare prevalence
Gout flare
18%
26
Observational data: associations, not effects.
Further findings
Factor associated with gout flare: GOUT-36 rule ≥ 2
| OR (95% CI) | ||
|---|---|---|
| GOUT-36 rule ≥ 2Only factor associated with gout flare | 5.46 (1.18–25.37) | |
| 0.050.21520Odds ratio (log scale) |
Hospital LOS
- Gout flare independently associated with hospital LOS; added 3 days
Baseline characteristics
- Gout flare: higher baseline sUA and lower use of ULT and flare prophylaxis vs without flare
Flare treatment
- One-third of flare episodes treated with ≥ 2 anti-inflammatory medications
Original publication
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. J Rheumatol. Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →